Axxelera
Private Company
Funding information not available
Overview
Axxelera is a Munich-based biotech company providing advanced high-density custom peptide microarray services for research and drug discovery. Its proprietary platform, which integrates solid-phase peptide synthesis with photolithography, allows for the rapid screening of millions of peptides with broad chemical and structural diversity. The company serves academic and industrial researchers globally, offering both full-service screening and array products to accelerate binder characterization and epitope discovery. As a private, likely early-revenue company, Axxelera is positioned as a critical enabler in the biologics and immunotherapeutics development pipeline.
Technology Platform
Proprietary high-density custom peptide microarray platform integrating solid-phase peptide synthesis with photolithography. Enables synthesis and screening of up to 200,000 custom peptides per array, incorporating unnatural amino acids and cyclization strategies for enhanced diversity and stability.
Opportunities
Risk Factors
Competitive Landscape
Axxelera competes with specialized peptide array providers (e.g., JPT, PepScan) and broader life science tools companies offering protein array solutions. Its key differentiators are extreme customizability, high density, and chemical diversity. Alternative competitive methods include phage display, yeast display, and NGS-based interaction assays.